v3.22.2
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Cash Flows from Operating Activities    
Net loss $ (6,527,048) $ (3,465,679)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 5,958 13,559
Share based compensation expense 415,033 862,000
Inducement expense 3,024,872
Amortization of debt premium (499,100)
Bad debt expense 13,500
Loss on extinguishment of convertible notes payable 2,196,100
Loss on disposal of property and equipment 9,610 92,804
Changes in operating assets and liabilities:    
Accounts receivable
Patient financing receivable, current portion 3,601 (22,990)
Patient financing receivable, net of current portion 26,699 (42,470)
Prepaid expenses and other assets (92,114) (30,445)
Accounts payable 114,067 (51,277)
Accrued liabilities (29,079) (68,390)
Other liabilities 42,140 57,498
Deferred revenue (414,025) (91,951)
Interest payable 80,090 6,712
Interest payable, related party 102,316
Net Cash Used in Operating Activities (1,527,380) (2,740,629)
Cash Flows from Investing Activities    
Purchase of property and equipment (7,832)
Net Cash Used in Investing Activities (7,832)
Cash Flows from Financing Activities    
Proceeds from notes payable 15,000 1,554,220
Proceeds from convertible notes payable 372,500 1,070,118
Payment of debt financing costs (13,250)
Proceeds from warrants exercised related to inducement 1,170,110
Payment on PPP Loan (66,275)
Net Cash Provided by Financing Activities 1,478,085 2,624,338
Net Change in Cash (49,295) (124,123)
Cash - Beginning of period 95,172 1,640,645
Cash - End of period 45,877 1,516,522
Supplementary Cash Flow Information    
Cash paid for interest 4,077 3,880
Non Cash Investing & Financing Activity    
Conversion of Series A Preferred Stock to Common Stock 7,309 17,804
Issuance of warrants pursuant to inducement agreements 2,993,872
Issuance of warrants for services rendered $ 31,000

Source